1,957 results match your criteria Journal of Crohn's and Colitis [Journal]


Efficacy, tolerability and safety of low volume bowel preparations in Inflammatory Bowel Diseases: The French multicentre CLEAN study.

J Crohns Colitis 2019 Feb 13. Epub 2019 Feb 13.

Department of Gastroenterology, University Hospital of Besançon, University Bourgogne Franche-Comté, Besançon, France.

Background: Standard high-volume polyethylene glycol (PEG) bowel preparations (PEG-4L) are recommended in inflammatory bowel disease (IBD) patients for colonoscopy. However, low-volume preparations (≤ 2 L of active volume) are often used in clinical practice. The aim of the study was to evaluate efficacy, tolerability and safety of the various bowel preparations in IBD, including low-volume preparations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz040DOI Listing
February 2019

A Validated Score Assessing the Risk for an Intra-Abdominal Abscess in Patients with Crohn's Disease Presenting at the Emergency Department.

J Crohns Colitis 2019 Feb 14. Epub 2019 Feb 14.

Institute of Gastroenterology and Liver Diseases, Department of Medicine, Hadassah - Hebrew University Medical Center, Jerusalem, Israel.

Background And Aims: A majority of acutely-ill Crohn's disease (CD) patients who present to Emergency Department (ED) will undergo an abdominal CT to rule out disease complications. We aimed to generate a simple non-invasive scoring model to predict the presence of an intra-abdominal abscess in CD patients in the ED.

Methods: We performed a retrospective case control study at four Israeli hospitals from January-1 st-2010 to May-30 th-2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz043DOI Listing
February 2019

Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.

J Crohns Colitis 2019 Feb 14. Epub 2019 Feb 14.

Department of Gastroenterology, Raigmore Hospital, Inverness.

Introduction: Vedolizumab is an anti-a4b7 monoclonal antibody that is licensed for the treatment of moderate to severe Crohn's disease and ulcerative colitis.

Aims: To establish the real-world efficacy and safety of vedolizumab in the treatment of inflammatory bowel disease.

Methods: Retrospective study involving six NHS health boards in Scotland between June 2015 and November 2017. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjz042DOI Listing
February 2019
1 Read

Health Care Transition Outcomes in Inflammatory Bowel Disease: a Multinational Delphi Study.

J Crohns Colitis 2019 Feb 14. Epub 2019 Feb 14.

Department of Paediatric Gastroenterology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands.

Background: Transition programs are designed to prepare adolescent Inflammatory Bowel Disease (IBD) patients for transfer to adult care. It is still unclear which outcome parameters define "successful transition". Therefore, this study aimed to identify outcomes important for success of transition in IBD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz044DOI Listing
February 2019
1 Read

Long-term outcomes of Proactive therapeutic drug monitoring of adalimumab and standard of care in patients with inflammatory bowel disease.

J Crohns Colitis 2019 Feb 7. Epub 2019 Feb 7.

Department of Gastroenterology, First Affiliated Hospital, China Medical University, Shenyang City, Liaoning Province, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz037DOI Listing
February 2019

Identification of Chitinase-3-like protein 1 as a novel neutrophil antigenic target in Crohn's disease.

J Crohns Colitis 2019 Feb 7. Epub 2019 Feb 7.

Institute for Biotechnology, Faculty of Environment and Natural Sciences, Brandenburg University of Technology Cottbus-Senftenberg, Universitätsplatz, Senftenberg, Germany.

Objective: There is an increasing incidence of inflammatory bowel disease (IBD). Autoimmune responses partake in the pathophysiology of IBD, however, its underlying pathways and target antigens are not yet fully elucidated.

Methods: Autoantigenic targets in IBD were identified after separation of whole cell proteins isolated from neutrophils using two dimensional electrophoresis and Matrix Assisted Laser Desorption Ionization - Time of Flight Mass Spectrometry (MALDI-TOF-MS) based protein identification of the spots that displayed Western blotting signals with anti-neutrophil cytoplasmic antibody (ANCA)-positive sera. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz012DOI Listing
February 2019
1 Read

IBD-associated colon cancers differ in DNA methylation and gene expression profiles compared to sporadic colon cancers.

J Crohns Colitis 2019 Feb 11. Epub 2019 Feb 11.

University of Chicago, Department of Public Health Sciences.

Background And Aims: As ulcerative colitis (UC)-associated colorectal cancer (CRC) and sporadic CRC differ in presentation and molecular features, we sought to evaluate differences in the impact of DNA methylation on gene expression.

Methods : NA methylation was assessed in 11 UC-CRCs and adjacent tissue and 11 sporadic CRCs and adjacent tissue using Illumina arrays. RNA sequencing was performed on 10 UC-CRCs and adjacent tissue and 8 sporadic CRCs and adjacent tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz014DOI Listing
February 2019
1 Read

Concerns and side effects of azathioprine during adalimumab induction and maintenance therapy for Japanese patients with Crohn's disease: a sub-analysis of a prospective randomized clinical trial (DIAMOND study).

J Crohns Colitis 2019 Feb 8. Epub 2019 Feb 8.

Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.

Background: Combining a thiopurine with the human anti-tumor necrosis factor- monoclonal antibody adalimumab for Crohn's disease (CD) treatment is controversial with regard to efficacy and safety. By conducting a sub-analysis of a multicenter, randomized, prospective, open-label trial (the DIAMOND study, UMIN registration number 000005146), we studied the risk of discontinuation of thiopurine in combination with adalimumab.

Methods: In the preceding DIAMOND study, we analyzed the: (i) timing and reasons for dropout in the monotherapy group and combination group; (ii) risk factors for dropout in the combination group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz030DOI Listing
February 2019
2 Reads

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.

J Crohns Colitis 2019 Feb 9. Epub 2019 Feb 9.

Division of Gastroenterology, Icahn School of Medicine at Mt Sinai, New York, NY, USA.

Background And Aims: Analyses of Crohn's Disease [CD] studies of anti-TNF agents, including adalimumab, have reported higher remission rates among patients with shorter disease duration. To further explore the relationship between disease duration and clinical efficacy, we analysed a larger patient cohort.

Methods: Data were pooled from 10 clinical trials in patients with moderately to severely active CD who received treatment with either adalimumab or placebo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy223DOI Listing
February 2019

Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in 2 Clinical Trials.

J Crohns Colitis 2019 Feb 6. Epub 2019 Feb 6.

Medical University of Vienna, Vienna, Austria.

Background And Aims: The efficacy and safety of adalimumab for induction and maintenance of clinical remission in patients with moderately to severely active ulcerative colitis were demonstrated in the ULTRA 1 and 2 clinical trials. This post-hoc, pooled analysis evaluated early changes in laboratory parameters, Mayo subscores, mucosal healing, and health-related quality of life.

Methods: Mean changes in laboratory parameters including albumin, high-sensitivity C-reactive protein, total protein, hematocrit, hemoglobin, and red blood cell and platelet counts, and Inflammatory Bowel Disease Questionnaire and Short Form 36 Questionnaire were evaluated from baseline to weeks 4 and 8. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz031DOI Listing
February 2019

Ciclosporin therapy after infliximab failure in hospitalized patients with acute severe colitis is effective and safe.

J Crohns Colitis 2019 Feb 6. Epub 2019 Feb 6.

University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA.

Background & Aims: Options for medical management of patients with acute severe colitis (ASC) failing IV steroids are limited and include rescue therapy with either infliximab or ciclosporin. In patients failing infliximab, second-line rescue therapy with ciclosporin is an alternative. The aim of this study was to investigate the efficacy and safety of ciclosporin in patients with steroid-refractory ASC failing first-line rescue therapy with infliximab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz032DOI Listing
February 2019
2 Reads

Faecal calprotectin is a very reliable tool to predict and monitor the risk of relapse after therapeutic de-escalation in patients with inflammatory bowel diseases.

J Crohns Colitis 2019 Feb 6. Epub 2019 Feb 6.

Inflammatory Bowel Disease Center University of Chicago Medicine, Chicago, Illinois, United States of America.

Background And Aims: To assess faecal calprotectin (Fcal) levels before and after therapeutic de-escalation to predict clinical relapse in patients with inflammatory bowel disease (IBD).

Methods: From a prospectively-maintained database, we enrolled 160 IBD patients (112 Crohn's disease/48 ulcerative colitis) in clinical remission, with Fcal measured within 8 weeks before therapeutic de-escalation. Clinical relapse was defined using Harvey-Bradshaw index or simple clinical colitis activity index. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz023DOI Listing
February 2019
1 Read

Decreased expression of cystathionine β-synthase exacerbates intestinal barrier injury in ulcerative colitis.

J Crohns Colitis 2019 Feb 5. Epub 2019 Feb 5.

Division of General Surgery, Peking University First Hospital, Beijing, China.

Background And Aims: Endogenous hydrogen sulfide (H2S) regulates multiple physiological and pathological processes in colon epithelial tissues. The current study investigated the role of cystathionine β-synthase (CBS), a major producer of H2S in colon epithelial cells, in the pathogenesis of UC-related intestinal barrier injury. The expression and DNA methylation level of CBS were investigated in inflamed and non-inflamed colon tissues collected from UC patients, and the effect of decreased CBS levels on Caco-2 monolayer barrier injury and altered status of tight junctions elicited by TNF/IFN was determined. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz027DOI Listing
February 2019
1 Read

Prospective Study of Psychological Morbidity and Illness Perceptions in Young People with Inflammatory Bowel Disease.

J Crohns Colitis 2019 Feb 5. Epub 2019 Feb 5.

Senior Lecturer and Clinical Psychologist Clinical Psychology Unit Department of Psychology University of Sheffield Cathedral, Sheffield.

Background And Aims: Psychological morbidity is increased in young people with inflammatory bowel disease (IBD). Illness perceptions may be an important factor. This study aimed to describe the prevalence and severity of psychological morbidity and examine relationships between baseline illness perceptions and anxiety, depression and health-related quality of life (HRQoL) at baseline and 12-months later in 16-21-years olds with IBD. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjz028DOI Listing
February 2019
2 Reads

Integrated psychological care is needed, welcomed and effective in ambulatory Inflammatory Bowel Disease management: Evaluation of a new initiative.

J Crohns Colitis 2019 Feb 5. Epub 2019 Feb 5.

Royal Adelaide Hospital.

Background And Aims: Inflammatory Bowel Disease is associated with psychosocial issues which reduce quality of life and impair medical management. However, these issues are rarely addressed in routine care. A model of integrated psychological screening and intervention was trialled to measure prevalence, patient participation, and potential benefits to mental health and/or quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz026DOI Listing
February 2019
1 Read

A simplified definition of histologic improvement in ulcerative colitis and its association with disease outcomes up to 30 weeks from initiation of therapy: Post-hoc analysis of three clinical trials.

J Crohns Colitis 2019 Feb 4. Epub 2019 Feb 4.

Department of Pathology, University Hospitals Leuven, Leuven, Belgium.

Background & Aims: Histologic evaluation is a meaningful complement to endoscopic and clinical measures in ulcerative colitis (UC). There is a need for a definition of histologic improvement that can be used in clinical trials, and any such definition must be predictive of disease outcomes.

Methods: Biopsies were collected from clinical trials (PURSUIT-SC [n=98], JAK-UC [n=219], and PROgECT [n=103]) in patients with moderate-to-severe UC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz022DOI Listing
February 2019
1 Read

Prevalence and Factors Associated with Fatigue in Patients with Inflammatory Bowel Disease: A Multicenter Study.

J Crohns Colitis 2019 Feb 5. Epub 2019 Feb 5.

Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid.

Aims: To determine the prevalence of fatigue in patients with inflammatory bowel disease (IBD), to identify the factors associated with fatigue and its severity, to assess the impact of fatigue on quality of life (QoL) and to evaluate the relationship between fatigue and sleep disorders.

Methods: Prospective multicenter study conducted at 22 Spanish centers. Consecutive patients followed at IBD Units were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz024DOI Listing
February 2019
3 Reads

CD4+ tissue-resident memory T-cells expand and are a major source of mucosal tumor necrosis factor α in active Crohn's Disease.

J Crohns Colitis 2019 Feb 4. Epub 2019 Feb 4.

Division of Gastroenterology, Department of Medicine, University of Michigan.

Background And Aims: Tumor necrosis factor (TNF)α and IL-17A producing T-cells are implicated in Crohn's disease (CD). Tissue-resident memory T (TRM) cells are tissue-restricted T-cells that are regulated by PR zinc finger domain 1 (PRDM1), which has been implicated in pathogenic Th17 cell responses. TRM cells provide host defense but their role in CD is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz010DOI Listing
February 2019

Ustekinumab exposure-outcome analysis in Crohn's disease only in part explains limited endoscopic remission rates.

J Crohns Colitis 2019 Jan 30. Epub 2019 Jan 30.

Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Background And Aims: Ustekinumab, an anti-IL12/23p40 monoclonal antibody, has been approved for Crohn's disease (CD). Real-life data in CD patients receiving ustekinumab intravenously (IV) during induction followed by subcutaneous (SC) maintenance are lacking. We assessed efficacy of ustekinumab and studied exposure-response correlations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz008DOI Listing
January 2019
1 Read

Carbohydrate Monotony as Protection and Treatment for Inflammatory Bowel Disease.

J Crohns Colitis 2019 Jan 30. Epub 2019 Jan 30.

Section of Pediatric Gastroenterology, Texas Children's Hospital Baylor College of Medicine.

The nutritional developmental origins of inflammatory bowel disease(s) (IBDs: Crohn's disease or Crohn disease [CD] and ulcerative colitis [UC]) and their diet-based treatments continue to receive increasing attention. There is growing evidence for the success of nutrition-based treatments, such as exclusive enteral nutrition (EEN) and the specific carbohydrate diet (SCD) in both pediatric and adult patients. Beyond these two dietary interventions, symptomatic benefit in IBD has also been shown from a gluten-free diet (GFD) and paleolithic diet (PALEO), among others. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjz011DOI Listing
January 2019
7 Reads

Intensified infliximab induction is associated with improved response and decreased colectomy in steroid-refractory paediatric ulcerative colitis.

J Crohns Colitis 2019 Jan 23. Epub 2019 Jan 23.

Division of Gastroenterology, Hepatology & Nutrition, Department of Paediatrics, University of Toronto, Toronto, ON, Canada.

Background: Infliximab pharmacokinetics in steroid-refractory ulcerative colitis (UC) suggest a need for higher dosing, but data concerning efficacy of intensification in this setting are lacking in children and inconsistent overall.

Methods: Paediatric patients (N=125) treated with infliximab for steroid-refractory or steroid-dependent UC were retrospectively reviewed. Outcomes (clinical response and remission, colectomy, mucosal healing, safety) with standard vs. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjz019DOI Listing
January 2019
4 Reads

Neutrophil Extracellular Traps Sustain Inflammatory Signals in Ulcerative Colitis.

J Crohns Colitis 2019 Feb 3. Epub 2019 Feb 3.

Department of Systems Medicine, University of 'Tor Vergata', Rome, Italy.

Background And Aims: In ulcerative colitis [UC], mucosal damage occurs in areas that are infiltrated with neutrophils. The antimicrobial function of neutrophils relies in part on the formation of extracellular web-like structures, named neutrophil extracellular traps [NETs]. The formation and/or clearance of aberrant NETs have been associated with several immune diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy215DOI Listing
February 2019

Vedolizumab Trough Levels and Histological Healing During Maintenance Therapy in Ulcerative Colitis.

J Crohns Colitis 2019 Jan 29. Epub 2019 Jan 29.

INSERM U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France.

Background & Aims: Histological healing may be the ultimate therapeutic goal in ulcerative colitis (UC). We investigated, for the first time, the association between vedolizumab trough levels and histological healing in UC.

Methods: This is a single-center retrospective cohort study including all consecutive UC patients on vedolizumab maintenance therapy who had a histological evaluation blindly to clinical data and underwent therapeutic drug monitoring, between June 2014 and March 2018. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjz029DOI Listing
January 2019
4 Reads

Genotype-guided thiopurine dosing does not lead to additional costs in patients with inflammatory bowel disease.

J Crohns Colitis 2019 Jan 30. Epub 2019 Jan 30.

Department of Human Genetics, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands.

Background And Aims: Decreased thiopurine S-methyltransferase (TPMT) enzyme activity increases the risk of hematologic adverse drug reactions (ADR) in patients treated with thiopurines. Clinical studies have shown that in patients with inflammatory bowel disease (IBD), pharmacogenetic TPMT-guided thiopurine treatment reduces this risk of ADR. The aim of this study was to investigate, whether this intervention impacts on healthcare costs and/or quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz009DOI Listing
January 2019
1 Read

Characterization of γδ T cells in intestinal mucosa from patients with early onset or long standing inflammatory bowel disease and their correlation with clinical status.

J Crohns Colitis 2019 Jan 21. Epub 2019 Jan 21.

Central Laboratory of Advanced Diagnosis and Biomedical Research (CLADIBIOR),University of Palermo, Palermo, Italy.

Background And Aims: Inflammatory bowel disease is a complex chronic inflammatory disease of the human gut with no clear etiology. Traditionally, dysregulated adaptive immune responses play an important role even though accumulating evidence suggest a role also for innate immunity. Because of the well known plasticity of γδ T cells, we investigated their percentage, phenotypical features and effector functions in the intestinal mucosa of early onset and long standing IBD patients, as compared to healthy subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz015DOI Listing
January 2019

Proactive therapeutic drug monitoring of adalimumab is associated with better long-term outcomes compared to standard of care in patients with inflammatory bowel disease.

J Crohns Colitis 2019 Jan 21. Epub 2019 Jan 21.

Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Background & Aims: Therapeutic drug monitoring (TDM) has proven to be effective for optimizing anti-TNF therapy in inflammatory bowel disease (IBD). Nevertheless, the majority of data refer to infliximab and reactive testing or association studies. We aimed to compare the long-term outcome of patients with IBD who received at least one proactive TDM of adalimumab with standard of care, defined as empiric dose escalation and/or reactive TDM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz018DOI Listing
January 2019

Novel Genetic Risk Variants Can Predict Anti-TNF Agent Response in Patients With Inflammatory Bowel Disease.

J Crohns Colitis 2019 Jan 21. Epub 2019 Jan 21.

Division of Gastroenterology and Hepatology Mayo Clinic, Rochester, Minnesota.

Background: It is important to identify patients with inflammatory bowel disease (IBD) refractory to anti-tumor necrosis factor (TNF) therapy to avoid potential adverse effects and adopt different treatment strategies. We aimed to identify and validate clinical and genetic factors to predict anti-TNF response in patients with IBD.

Materials And Methods: Mayo Clinic and Washington University IBD genetic association study cohorts were used as discovery and replicate datasets, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz017DOI Listing
January 2019

Relevant infections in inflammatory bowel disease, their relationship with immunosuppressive therapy and their effects on disease mortality.

J Crohns Colitis 2019 Jan 18. Epub 2019 Jan 18.

Hospital Universitari Mútua Terrassa.

Introduction: There is controversy as to whether the risk of relevant infection in IBD is related to immunosuppressants or the disease itself.

Aims: To evaluate: 1) the life-long prevalence and types of relevant infections in patients with IBD related to immunosuppressive treatment, and 2) the relationship of both infection and patient comorbidity to mortality.

Methods: Observational multicentre retrospective study of IBD patients that presented a relevant infection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz013DOI Listing
January 2019
1 Read

Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease.

J Crohns Colitis 2019 Jan 18. Epub 2019 Jan 18.

Laboratory for Complex Genetics, Department of Human Genetics, KU Leuven, Leuven, Belgium.

Background/aims: Early treatment of Crohn's disease (CD) is required to optimize patient outcomes. To this end, we need to gain a better understanding of the molecular changes at the onset of CD.

Methods: As a model for the earliest mucosal CD lesions, we study post-operative recurrent CD (Rutgeerts score ≥i2b). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz007DOI Listing
January 2019
3 Reads

Mesalazine-induced acute bacterial focal nephritis-like features in two pediatric patients with ulcerative colitis.

J Crohns Colitis 2019 Jan 8. Epub 2019 Jan 8.

Department of Pediatrics, Uji Tokushukai Medical Center, Uji, Kyoto.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy228DOI Listing
January 2019

C/EBPβ Deletion Promotes Expansion of Functionally Poor Intestinal Regulatory T Cells.

J Crohns Colitis 2019 Jan 9. Epub 2019 Jan 9.

Section of Pediatric Gastroenterology, Hepatology and Nutrition, Digestive Health Institute, Children's Hospital Colorado, Aurora, CO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy194DOI Listing
January 2019

The adipokine metrnl ameliorates chronic colitis in Il-10-/- mice by attenuating mesenteric adipose tissue lesions during spontaneous colitis.

J Crohns Colitis 2019 Jan 7. Epub 2019 Jan 7.

Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical College, Bengbu, China.

Background: Crosstalk between mesenteric adipose tissue (MAT) and the intestines affects the progression of Crohn's disease (CD). The adipokine metrnl regulates adipocyte function and has anti-inflammatory activity. We aimed to explore metrnl expression in CD MAT, investigate the influence of metrnl on the experimental colitis disease course and determine the mechanism underlying this effect. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjz001DOI Listing
January 2019
1 Read

Augmented Endoscopy for Surveillance of Colonic Inflammatory Bowel Disease: Systematic Review with Network Meta-Analysis.

J Crohns Colitis 2018 Dec 28. Epub 2018 Dec 28.

Gastroenterology, Department of Clinical Medicine and Surgery, School of Medicine "Federico II" of Naples, Naples, Italy.

Introduction: Considering the high risk of dysplasia and cancer in inflammatory bowel disease (IBD), surveillance is advocated. However, international guidelines do not reach a uniform recommendation on the way to perform surveillance. We performed a systematic review with a meta-analysis to assess the best endoscopic surveillance strategy in colonic IBD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy218DOI Listing
December 2018

The importance of molecular immune investigation in therapeutic clinical development for biomarker assessment.

J Crohns Colitis 2018 Dec 28. Epub 2018 Dec 28.

Genentech Inc, South San Francisco, California. USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy219DOI Listing
December 2018

Post-operative entero-cutaneous fistula closure by Over-The-Scope clip in Crohn's disease.

J Crohns Colitis 2018 Dec 29. Epub 2018 Dec 29.

Department of gastroenterology, Amiens University hospital, Picardie University, Amiens, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy227DOI Listing
December 2018
1 Read

Administration of the hyper-immune bovine colostrum extract IMM-124E ameliorates experimental murine colitis.

J Crohns Colitis 2018 Dec 12. Epub 2018 Dec 12.

Division of Gastroenterology and Hepatology, University Hospital and University of Zurich, Zurich, Switzerland.

Background/aims: Inflammatory bowel disease (IBD) is accompanied by lesions in the epithelial barrier, which allow translocation of bacterial products from the gut lumen to the host's circulation. IMM-124E is a colostrum-based product, containing high levels of anti-E.coli-LPS IgG and might limit exposure to bacterial endotoxins. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjy213DOI Listing
December 2018
9 Reads

Current Practices in Ileal Pouch Surveillance for Patients with Ulcerative Colitis: A Multinational, Retrospective Cohort Study.

J Crohns Colitis 2018 Dec 24. Epub 2018 Dec 24.

Department of Gastroenterology, Guy's & St. Thomas' NHS Foundation Trust, London, UK.

Background & Aims: There are no universally accepted guidelines regarding surveillance of UC patients after restorative proctocolectomy and ileal pouch-anal anastomosis (IPAA). There also exists a lack of validated quality assurance standards for performing pouchoscopy. To better understand IPAA surveillance practices in the face of this clinical equipoise, we carried out a retrospective cohort study at five IBD referral centres. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy225DOI Listing
December 2018
2 Reads

Transplantation of Human Intestine into the Mouse: A Novel Platform for Study of Inflammatory Enterocutaneous Fistulas.

J Crohns Colitis 2018 Dec 24. Epub 2018 Dec 24.

Koret School of Veterinary Medicine, Hebrew University of Jerusalem, Rehovot, Israel.

Background And Aims: Enteric fistulas represent a severe and medically challenging co-morbidity commonly affecting Crohn's disease [CD] patients. Gut fistulas do not develop in animal models of the disease. We have used transplantation of the human fetal gut into mice as a novel platform for studying inflammatory enterocutaneous fistulas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy226DOI Listing
December 2018
6 Reads

Systematic review and network meta-analysis Medical therapies to prevent recurrence of post-operative Crohn's disease.

J Crohns Colitis 2018 Dec 14. Epub 2018 Dec 14.

Department of Gastroenterology, Tallaght Hospital, Tallaght, Dublin 24, Ireland.

Background And Aims: Surgery is an important treatment for Crohn's disease (CD) but recurrence occurs in up to 80% of individuals post-operatively. The efficacy of several drugs to prevent post-operative recurrence has been studied in previous meta-analyses, but a number of randomised controlled trials (RCTs) have recently been published. We therefore performed an updated systematic review and network meta-analysis to investigate this issue. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy216DOI Listing
December 2018

Lymphoproliferative disease in the rectum 4 years after local mesenchymal stromal cell therapy for refractory perianal Crohn's fistulas: a case report.

J Crohns Colitis 2018 Dec 18. Epub 2018 Dec 18.

Dept. Gastroenterology and Hepatology, Leiden University Medical Center, The Netherlands.

Mesenchymal stromal cell (MSC) therapy is a new treatment for perianal fistulas in Crohn's disease. Although MSC-therapy shows a favorable safety profile, long-term safety data are limited. We detected an Epstein Barr virus (EBV) associated B cell lymphoproliferative lesion in the rectum of a patient 4 years after local administration of MSCs for his perianal fistulas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy220DOI Listing
December 2018

Inflammatory Bowel Disease and Physical activity: a study on the impact of diagnosis on the level of exercise amongst patients with IBD.

J Crohns Colitis 2018 Dec 18. Epub 2018 Dec 18.

Division of Gastroenterology, Mater Dei Hospital, Malta.

Background And Aims: IBD can impair the patients` functional capacity with significant negative effects on their quality of life. Our aim was to determine the impact of IBD diagnosis on fitness levels and to assess the levels of engagement in physical activity and fatigue in IBD patients` pre- and post- diagnosis.

Methods: A prospective multi-centre cross-sectional study was performed. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjy214DOI Listing
December 2018
8 Reads

Distinct histopathological features at diagnosis of very early onset inflammatory bowel disease.

J Crohns Colitis 2018 Dec 14. Epub 2018 Dec 14.

The Children's Hospital of Philadelphia, Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Philadelphia, PA.

Background And Aims: Children with very early onset inflammatory bowel disease represent a unique cohort, often with a severe phenotype that is refractory to conventional medications, and in some cases, have underlying primary immunodeficiencies. Prior work has identified distinct histopathological patterns in the gastrointestinal tract in patients with primary immunodeficiencies. The aim of this study is to characterize the diagnostic histological findings in patients with VEO-IBD as compared to older onset pediatric IBD and determine if there are unique pathological changes that can shed light on the driving forces of the disease, particularly immunodeficiencies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy212DOI Listing
December 2018
1 Read

The risk of inflammatory bowel disease in subjects presenting with perianal abscess: findings from the THIN database.

J Crohns Colitis 2018 Dec 13. Epub 2018 Dec 13.

Department of Gastroenterology, Sandwell and West Birmingham Hospitals NHS Trust, UK.

Background: Perianal abscess (PA) is associated with inflammatory bowel disease (IBD). The incidence of IBD after a diagnosis of PA and potential predictors of a future diagnosis of IBD are unknown.

Methods: The Health Improvement Network (THIN) is a primary care database representative of the UK population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy210DOI Listing
December 2018
1 Read

Intra-Cavitary Contrast-Enhanced Ultrasound: a Novel Radiation-Free Method to Detect Abscess Associated Penetrating Disease in Crohn's Disease.

J Crohns Colitis 2018 Dec 13. Epub 2018 Dec 13.

Department of Medical Ultrasonics, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Background And Aim: Penetrating disease is a common condition complicating Crohn's disease (CD). Establishing the presence of a fistula and the anatomical definition of the fistulous tracts are essential for deciding on appropriate treatment strategies. We aimed to assess the diagnostic accuracy of intra-cavitary contrast-enhanced ultrasound (IC-CEUS) for the detection of fistulous tract associated with abscesses in CD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy209DOI Listing
December 2018
6.234 Impact Factor

Assessment of Bowel Inflammation and Strictures by Magnetic Resonance Enterography in Long-term Crohn´s Disease.

J Crohns Colitis 2018 Dec 12. Epub 2018 Dec 12.

Department of Radiology, Akershus University Hospital, Lørenskog, Norway.

Background: Crohns disease (CD) is a chronic inflammation in the gut that often progresses to fibrosis. Magnetic Resonance Enterography (MRE) is an important diagnostic tool in evaluating CD. We aimed to assess the prevalence of inflammation and stricturing disease in patients with long-term CD and investigate associations with clinical factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy208DOI Listing
December 2018
3 Reads

Management of paediatric patients with medically-refractory Crohn's disease using Ustekinumab: A multi-centred cohort study.

J Crohns Colitis 2018 Dec 12. Epub 2018 Dec 12.

Division of Gastroenterology, Montreal Children's Hospital, Department of Paediatrics, McGill University, Montreal, Quebec, Canada.

Background: Ustekinumab (UST) is effective in the treatment of adults with moderate to severe Crohn's disease (CD). There is a paucity of data on its use in children.

Aim: To evaluate the response to UST in children with moderate to severe CD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy206DOI Listing
December 2018
21 Reads

Redefining the practical utility of blood transcriptome biomarkers in inflammatory bowel diseases.

J Crohns Colitis 2018 Dec 12. Epub 2018 Dec 12.

Department of Genetics, Maria Sklodowska-Curie Institute - Oncology Centre, Warsaw, Poland.

Background And Aims: The study investigates the practical utility of whole blood gene expression profiling to diagnose inflammatory bowel diseases (IBDs).

Methods: The discovery cohorts included 102 and 51 pediatric IBD patients and controls, and 95 and 46 adult IBD patients and controls, respectively. The replication cohorts included 447 and 76 pediatric IBD patients and controls, and 271 and 108 adult IBD patients and controls, respectively. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjy205DOI Listing
December 2018
17 Reads

Mucosal healing and bacterial composition in response to enteral nutrition versus steroid based induction therapy - a randomized prospective clinical trial in children with Crohn's disease.

J Crohns Colitis 2018 Dec 12. Epub 2018 Dec 12.

Hôpital Necker Enfants Malades Université Sorbonne Paris Cité, Paris, APHP.

Exclusive Enteral Nutrition (EEN) is as efficacious as corticosteroids (CS) to induce remission in Crohn's disease (CD), without their adverse effects. EEN seems to be more efficient than steroids to induce mucosal healing, but the underlying molecular mechanisms are only sparsely understood. We aimed in the present work to study the anti-inflammatory effects of EEN with Modulen IBD® versus CS in active pediatric CD and to assess its modulatory effects on the intestinal microbiota as compared to steroids. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy207DOI Listing
December 2018
6 Reads

Refractory pyoderma gangrenosum in a patient with Crohn´s Disease: complete response to Ustekinumab.

J Crohns Colitis 2018 Dec 7. Epub 2018 Dec 7.

Gastroenterology department, Hospital Garcia de Orta, Almada, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/ecco-jcc/jjy200DOI Listing
December 2018
2 Reads

Lack of the pH-sensing Receptor TDAG8 [GPR65] in Macrophages Plays a Detrimental Role in Murine Models of Inflammatory Bowel Disease.

J Crohns Colitis 2019 Feb;13(2):245-258

Department of Gastroenterology and Hepatology, University Hospital Zürich, University of Zurich, Switzerland.

Background: Tissue inflammation in inflammatory bowel diseases [IBD] is associated with local acidification. Genetic variants in the pH-sensing G protein-coupled receptor 65, also known as T cell death-associated gene 8 [TDAG8], have been implicated in IBD and other autoimmune diseases. Since the role of TDAG8 in intestinal inflammation remains unclear, we investigated the function of TDAG8 using murine colitis models. Read More

View Article

Download full-text PDF

Source
https://academic.oup.com/ecco-jcc/advance-article/doi/10.109
Publisher Site
http://dx.doi.org/10.1093/ecco-jcc/jjy152DOI Listing
February 2019
3 Reads
6.234 Impact Factor